---
title: The University of Edinburgh acknowledges Pelago patent and use of ​CETSA® process
description: Pelago Biosciences has announced the University of Edinburgh has acknowledged its Cellular Thermal Shift Assay (CETSA®) patent and use thereof in selected works in drug discovery research.
---

[Newsroom](https://news.lifesciencenewswire.com/newsroom)

# [The University of Edinburgh acknowledges Pelago patent and use of ​CETSA® process](https://news.lifesciencenewswire.com/newsroom/the-university-of-edinburgh-acknowledges-pelago-patent-and-use-of-cetsa-process)

 Written by [Life Science Newswire](https://news.lifesciencenewswire.com/newsroom/author/newswire) | Feb 27, 2024 12:00:00 PM

<https://drive.google.com/file/d/1URJrcM7CAo3KAlQK7KFhxaa-awBcdpzk/view?usp=drive_link>University of Edinburgh acknowledges Pelago Bioscience’s CETSA patent and use thereof in selected works in drug discovery research.

In connection with the CETSA® platform, the University of Edinburgh states:

*“The University of Edinburgh wishes to acknowledge the validity of Pelago’s CETSA patent (EP 2 699 910 B1) entitled “Methods For Determining Ligand Binding To A Target Protein Using A Thermal Shift Assay” (the “Patent”) and the use of the Cellular Thermal Shift Assay (CETSA®) process described in the Patent in relation to the following works: Carolin Temps et al., “A novel mode of inhibiting SRC improves drug efficacy and tolerability”, Cancer Research, 20 August 2021, DOI: 10.1158/0008-5472.CAN-21 0613; Chiara Asselborn, Kevin Myant and Alex von Kriegsheim, “Selective vulnerability of colorectal cancer (CRC) organoids to hypoxia-mimetic drug”, presented at the National Cancer Research Institute Cancer Conference in 2018; and; PhD student research to validate binding between integrin linked kinase and three compounds proposed to bind the protein undertaken in around February 2021”*

Michael Dabrowski, CEO of Pelago Bioscience comments on the agreement: We are grateful to the University of Edinburgh in their acknowledgement of our Patent. I encourage the drug discovery community to engage with Pelago Bioscience to explore the value that our patented CETSA® technology and services can bring to enhance their drug discovery efforts.

For more information about Pelago Bioscience and CETSA technology, please visit: [www.pelagobio.com](http://www.pelagobio.com)

About Pelago Bioscience:

Pelago Bioscience AB is a Discovery Research Partner serving the Drug Discovery community quantifying cellular target engagement of potential novel therapeutics from target validation to Candidate Drug nomination using our patented CETSA® technology platform.

[View full post](https://news.lifesciencenewswire.com/newsroom/the-university-of-edinburgh-acknowledges-pelago-patent-and-use-of-cetsa-process)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Life Science Newswire"
  },
  "dateModified" : "2024-02-27T12:00:00.582Z",
  "datePublished" : "2024-02-27T12:00:00Z",
  "headline" : "The University of Edinburgh acknowledges Pelago patent and use of ​CETSA® process",
  "image" : {
    "@type" : "ImageObject",
    "height" : 800,
    "url" : "https://f.hubspotusercontent30.net/hubfs/3338181/LSNewswire-main-header-banner-v2-1.jpg",
    "width" : 1920
  },
  "mainEntityOfPage" : "https://news.lifesciencenewswire.com/newsroom/the-university-of-edinburgh-acknowledges-pelago-patent-and-use-of-cetsa-process",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Newsroom"
  }
}
```